AdamMBrufskyMD

Professor of Medical Oncology, University Pittsburgh

Dr. Brufsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Halket Street
Suite 4628
Pittsburgh, PA 15213
Phone+1 412-641-6500

Fax+1 412-641-2256

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1992 - 1995
Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1992
Uconn School Of MedicineClass of 1990

PubMed

Journal Articles

Molecular Mechanisms Linking High Body Mass Index to Breast Cancer Etiology in Post-Menopausal Breast Tumor and Tumor-Adjacent Tissues
Adam M Brufsky, Tari A King, Susan B Brown, Breast Cancer Research and Treatment
Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...
H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Lectures

A Metastatic Breast Cancer Patient with Activating HER2 Exon 20 Insertion Mutation Responds to Poziotinib; A Case Report of Compassionate Drug Use
2019 ASCO Annual Meeting - 6/1/2019

Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint® and BluePrint® for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024December 12th, 2024
Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024December 11th, 2024
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC ConferenceNovember 8th, 2024
Join now to see all

Safety Study Of Recombinant Monoclonal AntibodyNational Center For Research Resources1999–2002
Rhumabher2/Cyclophosphamide/Doxorubicin And Placebo/Cyclophosphamide/DoxorucinbNational Center For Research Resources1998–2002
Recombinant Humanized Anti-185her2 Monoclonal Antibody In Breast CancerNational Center For Research Resources1998–2002
Liposomal Annamycin In Taxane Resistant Breast CancerNational Center For Research Resources1999–2000
Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1996–1998
Androgen Receptor Associated Proteins In Prostate CancerNational Cancer Institute1995